Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

No significant difference was observed in baseline demographics and MS characteristics among three treatment groups except past history of remission (Table 1).Baseline characteristics of three treatment groupsBaseline characteristicsPlacebo (n = 23)Metformin (n = 21)Pioglitazone (n = 16) p-valueAge (years) Mean (±SD)46.9 (±10.4)45.1 (±13.0)44.0 (±12.9)0.747Male/Females, n (%)14/9 (60.9/39.1)12/9 (57.1/42.9)9/7 (56.3/43.7)0.950Total duration of disease (years) Mean (±SD)9.1 (±8.6)6.0 (±6.9)6.9 (±11.2)0.492Seasonal Exacerbation, n (%)13 (56.5)13 (61.9)6 (37.5)0.313Seasonal improvement, n (%)13 (56.5)13 (61.9)5 (31.3)0.152Remission, n (%)21 (91.3)11 (52.4)10 (62.5)0.014Nail involvement, n (%)17 (73.9)13 (61.9)12 (75.0)0.602Joint involvement, n (%)7 (30.4)5 (23.8)4 (25.0)0.870DM, n (%)2 (8.7)3 (14.3)3 (18.6)0.653HTN, n (%)11 (47.8)10 (47.6)5 (31.3)0.523Family H/O Psoriasis, n (%)4 (17.4)3 (14.3)0 (0)0.225Alcohol, n (%)6 (26.1)8 (38.1)6 (37.5)0.643Smoking, n (%)3 (13.0)3 (14.3)1 (6.3)0.727Vegetarian, n (%)10 (43.8)11 (52.4)12 (75.0)0.144BMI (kg/m2), Mean (±SD)29.5 (±3.7)27.6 (±3.7)27.4 (±4.3)0.151Waist Circumference (cm), Mean (±SD)105.3 (±9.1)99.0 (±9.9)100.2 (±8.7)0.70ESI, Mean (±SD)5.9 (±1.6)5.3 (±1.5)5.4 (±1.3)0.412PGA, Mean (±SD)3.4 (±0.9)3.1 (±0.8)3.2 (±0.8)0.476FPG (mg/dl), Mean (±SD)97.6 (±20.8)101.9 (±35.1)103.4 (±28.9)0.797Total Cholesterol (mg/dl), Mean (±SD)184.4 (±37.5)206.9 (±36.2)207.2 (±42.3)0.95Triglycerides (mg/dl), Mean (±SD)181.8 (±61.3)194.3 (±63.1)200.1 (±55.9)0.623HDL (mg/dl), Mean (±SD)45.1 (±13.5)44.3 (±6.6)45.0 (±9.7)0.968LDL (mg/dl), Mean (±SD)107.6 (±35.7)126.1 (±29.1)123.1 (±42.3)0.194SBP (mmHg), Mean (±SD)130.4 (±11.5)130.6 (±12.9)135.6 (±11.5)0.344DBP (mmHg), Mean (±SD)84.7 (±7.9)85.9 (±7.9)85.6 (±8.5)0.875Calcium channel blockers, n (%)5 (21.7)3 (14.3)3 (18.6)0.815Beta blockers, n (%)2 (8.7)1 (4.8)0 (0)0.471Angiotensin receptor blockers, n (%)2 (8.7)2 (9.5)0 (0)0.456ACE inhibitors, n (%)1 (4.3)0 (0)1 (6.3)0.543Diuretics, n (%)0 (0)0 (0)1 (6.3)0.247Sulfonylureas, n (%)2 (8.7)0 (0)1 (6.3)0.403Anxiolytics, n (%)1 (4.3)1 (4.8)0 (0)0.684Lithium, n (%)1 (4.3)0 (0)0 (0)0.441Antidepressants, n (%)1 (4.3)2 (9.5)0 (0)0.413Insulin, n (%)0 (0)1 (4.8)0 (0)0.389Modafinil, n (%)0 (0)1 (4.8)0 (0)0.389NSAIDS, n (%)0 (0)1 (4.8)0 (0)0.389Ca, Vitamin D, n (%)0 (0)1 (4.8)0 (0)0.389Steroids, n (%)0 (0)0 (0)1 (6.3)0.247Beta 2 agonists, n (%)0 (0)0 (0)1 (6.3)0.247 DM diabetes mellitus, HTN hypertension, BMI body mass index, ESI erythema, scaling and Induration, PFA physician global assessment, FPG fasting plasma glucose, HDL high density lipoprotein, LDL low density lipoprotein, SBP systolic blood pressure, DBP diastolic blood pressure, ACE inhibitors angiotensin converting enzyme inhibitorsValues are presented as Mean (±SD) or n (%)

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Open-label reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This clinical trial was a single centre, parallel group, randomized, open label with blinded endpoint assessment of metformin, pioglitazone and placebo in psoriasis patients with MS satisfying inclusion and exclusion criteria.

Source: Methods.

Clinical photographs of patients were taken at baseline and post treatment.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)

Study design awaiting verification · BMC Dermatology · 2016

Original publication title

Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)

Surjit Singh; Anil Bhansali

© The Author(s). 2016

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Insulin sensitizers have shown improvement in the parameters of MS as well as disease severity in psoriasis patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Increased prevalence of metabolic syndrome (MS) is observed in psoriasis. Metformin has shown improvement in cardiovascular risk factors while pioglitazone demonstrated anti proliferative, anti-inflammatory and anti angiogenic effects. Study objective is to evaluate the efficacy and safety of Insulin sensitizers (metformin and pioglitazone) in psoriasis patients with metabolic syndrome (MS).

Source: Background

Abstract: What methods does the paper describe?

Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS.

Source: Methods

Abstract: Results

Statistically significant improvement was observed in Psoriasis Area and Severity Index (PASI), Erythema, Scaling and Induration (ESI) and Physician global assessment (PGA) scores in pioglitazone (p values: PASI = 0.001, ESI = 0.002, PGA = 0.008) and metformin groups (p values: PASI = 0.001, ESI = 0.016, PGA = 0.012) as compared to placebo. There was statistically significant difference in percentage of patients achieving 75 % reduction in PASI and ESI scores in metformin (p value: PASI = 0.001, ESI = 0.001) and pioglitazone groups (p vaue: PASI = 0.001, ESI = 0.001).

Significant improvement was observed in fasting plasma glucose (FPG) and triglycerides levels in metformin and pioglitazone arms. Significant improvement was noted in weight, BMI, waist circumference, FPG, triglycerides and total cholesterol after 12 weeks of treatment with metformin while pioglitazone showed improvement in FPG, triglyceride levels, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol and LDL cholesterol levels. There was no difference in pattern of adverse drug reaction in three groups.

Source: Results

Abstract: Conclusion

Insulin sensitizers have shown improvement in the parameters of MS as well as disease severity in psoriasis patients.

Source: Conclusion
Authors’ abstract

Background

Increased prevalence of metabolic syndrome (MS) is observed in psoriasis. Metformin has shown improvement in cardiovascular risk factors while pioglitazone demonstrated anti proliferative, anti-inflammatory and anti angiogenic effects. Study objective is to evaluate the efficacy and safety of Insulin sensitizers (metformin and pioglitazone) in psoriasis patients with metabolic syndrome (MS).

Methods

Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS.

Results

Statistically significant improvement was observed in Psoriasis Area and Severity Index (PASI), Erythema, Scaling and Induration (ESI) and Physician global assessment (PGA) scores in pioglitazone (p values: PASI = 0.001, ESI = 0.002, PGA = 0.008) and metformin groups (p values: PASI = 0.001, ESI = 0.016, PGA = 0.012) as compared to placebo. There was statistically significant difference in percentage of patients achieving 75 % reduction in PASI and ESI scores in metformin (p value: PASI = 0.001, ESI = 0.001) and pioglitazone groups (p vaue: PASI = 0.001, ESI = 0.001).

Significant improvement was observed in fasting plasma glucose (FPG) and triglycerides levels in metformin and pioglitazone arms. Significant improvement was noted in weight, BMI, waist circumference, FPG, triglycerides and total cholesterol after 12 weeks of treatment with metformin while pioglitazone showed improvement in FPG, triglyceride levels, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol and LDL cholesterol levels. There was no difference in pattern of adverse drug reaction in three groups.

Conclusion

Insulin sensitizers have shown improvement in the parameters of MS as well as disease severity in psoriasis patients.

Trial registration

CTRI Registration Number: CTRI/2011/12/002252. Registered on 19/12/2011.

Publication and source details

Original title: Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)

Surjit Singh; Anil Bhansali

BMC Dermatology · 2016

© The Author(s). 2016https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T20:00:40.268805+00:00

DOI: 10.1186/s12895-016-0049-y · PMC4987981